Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care
JERUSALEM, Nov. 19, 2025 /PRNewswire/ -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract is valued at up to $186 million, including all option periods.
This pivotal collaboration, which represents Rafa's second major contract with BARDA, addresses an urgent global need: a rapidly deployable, easy-to-administer treatment for hemorrhage in the critical prehospital setting.
Addressing the Critical Window to Save Lives
Uncontrolled bleeding is the leading cause of preventable death following trauma, whether caused by accidents, mass-casualty events or in the battlefield. Caregivers need a tool which can be easily administered to a large number of casualties in a short period of time. TXA is an antifibrinolytic agent commonly used off label around the world to treat trauma bleeding in the pre-hospital and hospital space.
Landmark clinical studies performed in tens of thousands of individuals have demonstrated that TXA can significantly reduce mortality rates if administered quickly enough following trauma hemorrhagic injury.
"The clock starts ticking the moment a patient sustains a hemorrhagic injury, and the few minutes before reaching a hospital are the most critical ones," said Roy Shay, Vice President of Biodefense at Rafa Laboratories. "Currently, TXA is typically administered intravenously (IV), which is challenging, time-consuming and requires training. The need for trained individuals even greater in high-stress, or mass-casualty situations. Developing a new intramuscular TXA injection is a potential game-changer as it simplifies the administration process, especially if administered with an autoinjector.
As planned under the potential scope of this project, Rafa shall also develop a TXA autoinjector which will enable professional as well as nonprofessional care givers to deliver this essential treatment instantly—dramatically increasing survival chances worldwide."
"The IM route offers a fast, reliable, and user-friendly alternative for the existing IV administration, which can be extremely difficult in patients experiencing severe shock".
BARDA and Rafa are Collaborating on a Comprehensive Development Approach
Rafa Laboratoriesis adopting a robust and integrated product development approach, which is planned to include formulation development, manufacturing scale-up, pre/clinical trials and a streamlined regulatory pathway designed to secure U.S. Food and Drug Administration (FDA) approval.
"Over the past four decades, Rafa has built a reputation for developing highly dependable medical countermeasures targeting acute, life-threatening conditions, mainly CBRN and pain management." said Iddo Leshem, Chief Executive Officer of Rafa Laboratories. "The IM TXA development contract marks a strategic expansion of Rafa's presence in acute trauma care. We are deeply committed to partnering with BARDA to accelerate the delivery of this urgently needed, life-saving solution to hundreds of thousands of patients across the globe".
About Rafa Laboratories
Founded in 1937 and headquartered in Jerusalem, Israel, Rafa Laboratories is a global leader in biodefense and emergency medical solutions. For more than 40 years, Rafa has supplied medical countermeasure autoinjectors to the U.S. federal government, NATO allies, military forces, and civilian stockpiles worldwide, including its Midazolam 10 mg autoinjector (US-FDA approved under NDA #216359 since 2022) and Atropine autoinjector (US-FDA approved under NDA #212319 for 2 mg since 2018 and EUA # for 0.5 & 1 mg since 2017). The company's expertise spans the entire value chain — from a robust R&D pipeline addressing emerging threats, to cGMP-compliant manufacturing and successful regulatory approvals from the U.S. FDA and European health authorities.
Rafa's controlling shareholder, FIMI Opportunity Funds, is Israel's leading private equity fund. With over 25 years of experience, FIMI manages assets of $7 billion and has completed nearly 100 investments globally.
This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50125C00018.
Media Contact:
Roy Shay
VP, Biodefense
Rafa Laboratories
[email protected]
SOURCE Rafa
Share this article